MAPT and tauopathy: In summary, the present study aimed at understanding the molecular mechanisms underlying the beneficial action of 12A12mAb will not only move forward its preclinical development to a candidate for the treatment of patients affected by AD but also will improve our knowledge of the tau pathobiology in vivo in the context of human tauopathies.